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Summary and Key Points 
1. Oncology surgery includes operations to diagnose malignancy 
(biopsies), to remove known cancer of the primary tumor and 
metastases, and for palliation. 
2. A fifth category of oncology surgery, reconstructive surgery, is not 
strictly speaking, cancer surgery, but practically all cancer operations 
involve some reconstruction. Frequently, plastic or vascular 
surgeons assist with this phase of the procedure. 
3. Tumor resection with a margin of normal tissue (R0 resection) is the 
aim of radical cancer operations. 
4. Surgical Oncology is a disease based discipline; surgical oncology 
fellowships prepare surgeons in the multi-disciplinary approach to 
the prevention, diagnosis, treatment, and rehabilitation of cancer 
patients. 
5. Fellowships also prepare members of surgical subspecialties to 
interact with other oncologic disciplines and to provide leadership in 
the surgical, medical, and public health community in oncologic 
related matters. 
Introduction 
Surgery is a branch of medicine that developed primarily around the 
management of wounds, infections, and bladder stones. Along the way, 
it also became the primary treatment modality for malignant solid tumors. 
For many cancers surgical resection remains the foundation of curative 
treatment. This chapter aims to introduce the history of cancer surgery, 
to answer the question of “What is a surgical oncologist?”, and to discuss 
the different categories of cancer surgery. 
Surgical treatment for malignant disease has been employed with 
varying degrees of success since ancient times. Celsus, a physician 
during the Roman Empire once wrote, “After excision, even when a scar 
has formed, none the less the disease has returned.” It was a long held 
belief that cancer was an incurable malady and often the treatments 
were more harmful than the cancer itself. 
The foundation of modern surgical oncology practice was developed 
over a relatively short historical period (1840-1940), often referred to as 
“the century of the surgeon”. The discovery and introduction of general 
anesthesia (1840s) allowed for slower more complex surgical 
interventions. In addition, the development of antiseptic surgery (1860s) 
improved surgical morbidity and mortality. Finally, technical advances in 
tissue microscopy hastened the discovery of unmediated cell growth that 
lies at the center of cancer biology that we now know to be the result of 
genetic mutations. Three surgeons are credited with the founding of 
“cancer operations” including Dr. Christian Albert Theodor Billroth of 
Germany, Dr. W. Sampson Handley of London, and Dr. William Stewart 
Halsted of Baltimore. Prospective surgeons will be interested in the 
history of the development of cancer surgery. 
What is Surgical Oncology? 
Broadly defined, surgical oncology refers to that discipline of surgery 
which concerns itself with the management of cancer. Since this is such 
a broad field, there are different kinds of surgical oncologists, many 
defined based on their organ (colorectal surgeons, urologists, 
gynecologic oncologists, ear nose and throat surgeons, orthopedic 
surgeons) or body cavity of interest (thoracic surgeons and 
neurosurgeons). Most of these aforementioned specialties manage both 
benign and malignant disorders. These disciplines are not to be 
confused with the surgical specialty which is almost exclusively devoted 
to oncology and is disease-based rather than organ- or cavity-based and 
is called surgical oncology. Fellowship-trained surgical oncologists are 
recruited from General Surgery residency and receive additional 
multidisciplinary experience in the treatment of malignancies of the head 
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and neck region (although not in the brain), breast, abdominal cavity, and 
skin and soft tissue (including melanoma and sarcoma) in two- or three- 
year programs accredited by the Society of Surgical Oncology (SSO) 
and the Accreditation Council for Graduate Medical Educations 
(ACGME). As a result, they are often experienced in a number of 
complex cases requiring intensive, multidisciplinary treatment. These 
fellowships prepare individuals to interact with other oncologic disciplines 
and to provide leadership in the surgical, medical, and public health 
community in oncologic related matters. The special skills provided by 
surgical oncology fellowships has now been recognized on the national 
level with the creation of a certificate in complex general surgical 
oncology provided by the American Board of Medical Specialties (ABMS) 
since March 2013. Recently, the SSO has begun accrediting more 
focused training programs such as breast surgical oncology. 
Other surgical subspecialties have developed increasing expertise in 
operations for cancer: 
 Thoracic surgeons, who belong to a specialty that evolved to 
manage the complications of tuberculosis in the pre-antibiotic 
era, are frequently the specialists operating on patients with lung 
cancer. 
 Gynecologic, genitourinary, central nervous system (CNS), and 
skeleton malignancies have also almost always been claimed by 
their respective subspecialty disciplines outside surgical 
oncology. 
Although a surgical oncologist certainly has the ability and training to 
perform complex surgeries for cancer expertly, a significant amount of 
the added value of subspecialty training is intellectual rather than 
technical. Surgical oncology programs include rotations in medical 
oncology, radiation oncology, and pathology in order to build a significant 
fund of knowledge in the biology of cancer and the other therapies 
needed in conjunction with surgery to cure or palliate cancer patients. 
This global perspective on treatment options allows for a more tailored 
plan of care. 
Selecting the patient for a complex operation, at the optimal time in the 
patient’s overall treatment plan can be complicated due to the local and 
systemic effects of chemotherapy or radiation. By extending the 
experience to nonsurgical disciplines, the surgical oncologist can 
understand the likely pitfalls of operating on patients who have had or will 
have multidisciplinary treatment. Finally, surgical oncologists frequently 
have experience with rare tumors and unusual situations. The discipline 
has a deeply engrained cultural expectation that its practitioners will 
make a significant attempt to improve the care of the cancer patient 
through research and teaching. 
Types of Cancer Surgery 
There are four categories of cancer surgery: 
1. Operations performed for lumps, bumps, spots and ulcers 
because they might be malignant. 
2. Operations performed to extirpate (completely remove) a known 
cancer with anatomic reconstruction to optimize function when 
appropriate. 
3. Operations performed to extirpate metastatic disease. 
4. Operations performed to improve quality of life and relieve 
symptoms related to cancer (palliative surgery). 
A fifth category of surgery, reconstructive surgery, is not strictly speaking 
cancer surgery, but practically all cancer operations involve some 
reconstruction. 
Each category has principles and challenges, and is best appreciated 
within the context of a particular tumor type or situation. This will be 
addressed in greater depth in the organ-specific chapters. Nevertheless, 
there are general observations that can be made about each of them. 
1. Operations done to diagnose cancer for a lump, spot (on the skin or 
on a CT scan), or ulcer are called biopsies and should take into 
account what comes next if the diagnosis of malignancy is 
confirmed. Biopsies can be categorized as ‘excision’ or ‘incision’, 
with the latter being the removal of only a portion of the suspected 
malignancy. If on confirmation of cancer a larger or wider resection 
follows, the operative incision should be planned to avoid 
unnecessarily contaminating normal tissues and so that it can be 
encompassed easily in the subsequent resection specimen without 
having to sacrifice more normal tissue than necessary. If the 
operation required to establish a diagnosis is sufficiently “large” so 
that going back to resection more tissue seems unnecessarily 
invasive, then the original operation should be conducted as if the 
specimen in question really did have a cancer in it, effectively 
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performing an excision biopsy and a potentially curative cancer 
resection at the same time. An example of this is a segmental 
colectomy for a large villous adenoma with atypia in the endoscopic 
biopsy specimens. It is more efficacious to remove that section of 
colon with the lymph nodes in the mesentery attached (fairly easily 
accomplished without much extra operating or morbidity) as you 
would in a cancer operation, rather than simply taking out a small 
piece of colon and then re-operating on the patient’s abdomen 
through the previous scar tissue for a wider resection of colon and 
lymph nodes when the villous adenoma turns out to be a cancer. 
This type of approach to lumps, spots and ulcers needs to be 
balanced by a realistic appreciation of the extra and unnecessary 
morbidity that might accompany radical resection of a benign 
condition. Fortunately, less invasive needle biopsies, core biopsies, 
and incisional biopsies often remove uncertainty in this area of 
cancer surgery. 
2. Operations done to extirpate a known primary malignant tumor 
should be done without cutting across the tumor or any of its 
extensions. The operation is often done best without actually seeing 
the primary tumor. If the tumor extends into an adjacent structure or 
organ, the surgeon should resect that structure rather than 
separating the tumor from it. Of course, if that structure cannot really 
be sacrificed without threatening the patient’s life (e.g. you can’t 
really resect the blood supply to the liver), or function (e.g. if you 
sacrifice all the nerves to the leg so that it is insensate and 
paralyzed, preserving the leg becomes pointless), or cosmesis (e.g. 
taking the eyelids), then one may compromise on the margin if 
reconstruction is not a viable choice. How wide that margin of normal 
tissue around a malignant tumor needs to be is a source of endless 
fascination and controversy. It suffices to say that it is different for 
different tumors and other modalities such as radiation can help 
narrow that width. The resection is only as good as the closest 
margin. It makes little sense to sacrifice an important functional 
organ on one side of a tumor to achieve a nice wide margin there if 
the surgeon plans to shave the tumor off another structure on the 
other side. 
The extent of tumor before treatment significantly affects the chance 
of successful resection, and may suggest preoperative) neoadjuvant) 
treatment is indicated to improve the chance of complete removal of 
the tumor (Figure 1). 
 
Figure 1. Preoperative images of esophageal cancer in distal esophagus 1a. 
Tumor has extended to edge of esophagus, and not touched aorta. R0 
resection is likely. 1b. Tumor has extended beyond esophagus and touched 
or invaded aorta. This situation may be discovered by preoperative 
endoscopic ultrasound or CT. Image drawn by Sarah Alyssa Uy. 
Resections where the surgeon cuts across grossly appreciable tumor 
are called R2 resections (Figure 2). Resections with grossly clear 
margins, but microscopically positive, are termed R1 resections 
(Figure 3). If the margins are both grossly and microscopically clear, 
it is termed an R0 resection. R0 resections are the aim of cancer 
operations (Figure 4). Fortunately, modern imaging allows surgeons 
to judge the likelihood of R2 resections before actually operating on 
the patient (Figures 5a & b and 6a & b). This is important because 
R2 resections rarely have a favorable impact on the natural history of 
the cancer and can be quite morbid for the patient. Debulking 
surgery, also called cytoreductive surgery, is a first cousin of R2 
resections and by itself is almost always unhelpful, except for some 
specific situations such as surgery for carcinomatosis in ovarian 
cancer, pseudomyxoma peritonei, or palliation for neuroendocrine 
tumors. The decision to take a patient for debulking surgery should 
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be made in the context of a multidisciplinary tumor board. The 
conceptual difference between R2 and debulking surgery is the 
intention– R2 resections generally do not intend to leave gross 
tumor, whereas debulking surgery is undertaken with the expectation 
that some tumor will be left behind. R1 resections do not necessarily 
guarantee a local recurrence of the tumor. In fact, while R1 
resections are associated with significantly worse overall survival 
and higher rates of local recurrence than R0 resections, rates of local 
recurrence are still often significantly less than 30%. The effects of 
R1 resections can many times be mitigated by the use of adjuvant 
radiation. 
 
Figure 2. R2 Resection. Esophageal cancer after cut-through resection with 
gross tumor remaining in patient. Image drawn by Sarah Alyssa Uy. 
 
Figure 3. R1 Resection. Black dots on aorta represent microscopic cancer 
cells left behind. These may be suspected because the surgeon had to 
shave the tumor off an adjacent structure she does not wish to resect, or 
because the pathologist identifies tumor on the cut margin of the specimen 
(positive margin) or because the patient was injected with a radioactive 
labeled antibody to the tumor, which is found .with a tiny handheld radiation 
detector. Image drawn by Sarah Alyssa Uy. 
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Figure 4. R0 Resection. No tumor is left on aorta, pathologic specimen margin is 
negative. Image drawn by Sarah Alyssa Uy. 
 
 
Figure 5. Non-contrast enhanced CT of esophageal cancer patient’s chest. 
Image on left shows some oral contrast; image on right, which is caudad, 
demonstrates that the esophageal canal is almost completely occluded, with 
just a dot of contrast in the esophageal canal. Note fat plane between aorta 
and enlarged esophagus, which suggests this patient’s tumor will be 
resectable with clean margins (R0). Images courtesy of the University of 
Massachusetts Medical School, Department of Radiation Oncology. 
 
Figure 6. Two axial IV and oral contrast enhanced CT slices of esophageal 
cancer patient. Image on left is cephalad, and esophageal wall looks normal; 
a bit of contrast is visible in canal. Image on right shows thickened 
esophageal wall, but canal is still widely patent. Small arrows point at area of 
suspected infiltration into fat, but there appears to be clear fat between this 
infiltration and vena cava. In this direction, a clear margin is likely despite 
extra-esophageal extension. There does not appear to be a fat plane 
between esophageal tumor and anterior wall of aorta, suggesting that an 
attempt to resect tumor (without neoadjuvant treatment) may leave tumor 
cells on the aorta (R1). Images courtesy of the University of Massachusetts 
Medical School, Department of Radiology. 
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Tumors may spread or metastasize through lymphatics, blood flow, 
or local extension. For tumor types which spread to lymph nodes, 
removal of the local/regional lymph nodes is an important component 
of the resection for that cancer. Sarcomas- malignancies derived 
from tissues of mesenchymal embryonic origin (soft tissue and bone) 
are an example of a tumor type which typically does not metastasize 
to the local and regional lymph nodes. Therefore, these lymph nodes 
are not typically sampled or removed in sarcoma resections. For 
most malignancies derived from epithelial tissues- carcinomas- the 
lymph nodes are removed because these tumors do metastasize to 
them. 
Removal of lymph nodes containing tumor may be diagnostic for 
staging, curative, or both. Conventional modern opinion is that 
involvement of local/regional lymph nodes simply predicts the biology 
of the cancer and most often implies a poor prognosis. An older 
conventional wisdom held that local regional lymph nodes were 
barriers to the spread of a cancer that cancer cells needed to 
colonize first before they spread to distant organs. Although it is clear 
that this older view of the metastatic process is inaccurate, it still 
animates the rationale for many cancer operations. 
As is the case for margins, the extent, timing, and value of lymph 
node removal has been a source of enduring discourse and 
continues to evolve over time. There is vast literature on this topic 
because lymph node resections potentially come with major 
morbidity to patients, for example, lymphedema. There are two 
technical types of lymph node resection: sentinel lymph node biopsy 
(where only the first 1-3 lymph nodes that directly drain the tumor are 
removed and evaluated) and complete lymphadenectomy (where all 
of the lymph nodes in the draining basin are removed). Complete 
lymphadenectomy carries a much higher morbidity than sentinel 
lymph node biopsy. 
Several general points have survived controversy by the weight of 
accumulated evidence. It is clear that determining whether the local 
and regional lymph nodes are involved by a cancer usually provides 
critical prognostic information that may guide treatment options for 
the patient. For several cancers (e.g. breast and melanoma), 
information may be acquired from a clinically negative lymph node 
basin (i.e. no palpable lymph nodes on examination) using sentinel 
lymph node biopsy. It is accepted that removing clinically involved 
lymph nodes along with the primary tumor improves outcomes for 
many cancers. However, if evaluation of an entire lymph node basin 
does not prove to carry prognostic or survival advantages, it may be 
unnecessary to submit the patient to these procedures. Evidence for 
the benefit of lymph node dissection has evolved over time, often 
due to advances in systemic therapy. For example, a current  study, 
the American College of Surgeons Oncology Group Z0011 trial 
(ACOSOGZ11) showed lymph node sampling alone (sentinel node 
biopsy) was non-inferior to removal of all the lymph nodes in the 
axilla for certain women with invasive breast cancer and known 
lymph node metastasis.1 
3. Operations performed to extirpate metastatic disease are a relatively 
new facet of cancer surgery. Previously, the presence of metastatic 
disease was considered to be a relative contraindication for any 
surgery aimed at cure. The presence of metastases was evidence of 
systemic disease and as a consequence it was determined that only 
a systemic therapy such as chemotherapy would be of benefit in 
controlling disease progression and improving outcomes. 
The success of local therapy (i.e. operations) for systemic disease is 
real and is based on the so called “seed and soil” hypothesis used to 
describe the process of metastasis. The idea is that cancer cells (the 
seeds) must find the right soil (target organ) in which to germinate. 
While the distribution of the seeds might be random (via the wind or 
the blood stream) the subsequent growth of colonies will be targeted. 
In circumstances where the pattern of metastases is relatively 
predictable (e.g. sarcoma metastases to lung or colon metastases to 
liver), and/or limited (i.e. one or two metastases is best), a local 
therapy such as complete surgical extirpation of the metastases can 
cure some patients. The key to success with this approach is careful 
patient selection. Generally, good selection leads to approximately 
20% long-term survival rates across a remarkable variety of tumor 
types and target organ sites. Tighter selection policies lead to 
somewhat better cure rates and looser selection policies lead to 
worse outcomes. Combining metastasectomy with an effective 
chemotherapeutic regimen appears to improve long- term outcomes 
in most circumstances. 
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The four principal components of appropriate patient selection for 
metastasectomy include: 
I. The primary tumor must be already controlled or be 
controllable. 
II. The metastases should be limited to one target organ and 
that should be the expected target organ for metastases 
from that tumor type. 
III. The metastases should be limited in number – the fewer the 
better. At the very least, the surgeon should be able to 
remove all metastases completely without significant 
mortality due to precipitating physiologic failure of the target 
organ in which the metastases are found (e.g. lung or liver 
failure); removing metastases partially does not improve 
cancer-related survival. 
IV. There should be no other better single therapeutic options 
such as an effective chemotherapy for that tumor. Resection 
of locally recurrent malignancies and cytoreductive surgery 
with intra-abdominal chemotherapy for peritoneal 
metastases from tumors such as ovarian cancer and 
appendiceal cancer is another type of cancer surgery which 
is somewhat related to operations for metastatic disease. It 
derives much of its rationale from the seed and soil 
hypothesis, much of its success from very similar patient 
selection principles, and achieves fairly similar outcomes in 
appropriately selected patients. 
4. Operations performed to palliate malignant tumors are a very 
important part of surgical oncology and all the surgical disciplines 
that operate on cancer patients. These are operations which are 
undertaken to relieve obstruction (of the bowel, ureters, bile duct, 
etc.), control bleeding or acute perforations, manage fistulas, and 
manage tumors that are breaking down, fungating, ulcerating or 
causing significant suffering in terms of quality of life. Sometimes 
these operations are performed to relieve pain. The important 
principle is that these procedures are undertaken to relieve a 
symptom, not to try to cure the patient of their cancer. 
The term palliative surgery is frequently misused; it is often used to 
describe an operation that a surgeon undertook to cure a patient of 
their tumor, which in retrospect has not succeeded (e.g. an R2 
resection, or a failed metastasectomy). It is worth noting in this 
regard that many patients with primary tumors, and most patients 
who are candidates for metastasectomy, are either asymptomatic or 
minimally symptomatic. Sometimes palliative surgery is 
inappropriately used to describe operations to extirpate tumors in 
which there is simply a very low rate of long term survival (e.g. for 
cancers of the esophagus or pancreas) even though the operation is 
potentially curative. 
Finally, the term palliative surgery can be confused with the notion of 
prophylactic palliation; an operation done to prevent the appearance 
of unmanageable symptoms later. An example of this operation 
would be a distal gastrectomy performed for a cancer that was 
discovered as the result of a work up for guaiac positive stools (no 
other symptoms), and at operation is discovered to have small 
peritoneal implants. The rationale for proceeding with the 
gastrectomy in this instance is to prevent future problems with 
obstruction and bleeding, it is not to try to cure the patient. 
Prophylactic palliation is a traditional rationale for cancer resections, 
although for the most part there is no evidence to support its 
practice. These semantic issues are important because they prevent 
clarity of thought and purpose around what a surgeon or a care team 
is actually going to be able to accomplish for a patient with a difficult 
tumor, and thus can contribute to poor decision making and 
unnecessary suffering. 
When considering a palliative operation, it is helpful to keep in mind 
that you cannot make a symptom better if the patient is 
asymptomatic. Many operative procedures will have their own set of 
side effects, and it typically takes otherwise well patients about two 
months to recover completely from open abdominal or thoracic 
surgery. Patients who require palliative surgery usually are not that 
healthy, frequently have higher operative complication rates, and 
typically have a limited life expectancy – often measured in months. 
So, the decision making concerning palliative operations is not 
straightforward. Fortunately, there are an increasing number of less 
invasive tools that can be used to palliate many conditions. 
For example, obstructions of the biliary tree are routinely handled by 
stents that can be placed percutaneously through the liver or 
endoscopically. Endoscopically placed stents are also used for 
esophageal, gastroduodenal, and even colorectal and tracheal 
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obstructions. Radiation is often an effective way to handle raw tumor 
surfaces that are bleeding. Thoracoscopic and laparoscopic 
procedures when possible can minimize the morbidity of operations 
in the chest and abdomen. Repeated nerve blocks can be 
accomplished percutaneously to control pain. It is important to 
consider all of these issues as well as a variety of alternative 
approaches when contemplating a palliative operation. There is an 
old surgical saying that, “No problem is so bad that the wrong 
operation can’t make it worse”. Nevertheless, frequently a clearly 
conceived and well thought out operation can relieve suffering and 
prolong life, even if it does not cure the cancer. 
Reconstructive surgery is a type of surgery that is not strictly 
speaking cancer surgery. However, practically all cancer operations 
involve some degree of reconstruction (Figure 7). Often this 
reconstruction is handled by the primary oncologic surgeon; 
especially when the reconstruction is relatively straightforward (e.g. 
creation of anastomosis), or when the need for flaps is so common 
that the oncologic surgeon develops a basic repertoire of simple 
flaps (e.g. head and neck surgeons and melanoma surgeons). 
However, some reconstructions are more complex. For example, 
major vascular resections may require facility with vascular grafts 
and patch reconstruction. Many cancer surgeons rely on colleagues 
in vascular surgery in these circumstances. Even more commonly, 
the primary oncologic surgeon may require the assistance of a 
colleague in plastic surgery to rotate tissue flaps or perform free 
tissue transfers to cover radiated fields, large defects that would not 
heal primarily, or simply to achieve a socially acceptable cosmetic 
result. Indeed, modern advanced cancer surgery probably cannot be 
practiced optimally without capable and gifted plastic surgeons on 
the team. This reemphasizes the point that, whatever the training 
background of the primary cancer surgeon is, surgical care of a 
modern cancer patient is best approach in a multidisciplinary 
manner. 
 
Figure 7. Reconstruction of the gastrointestinal tract. Stomach has been 
mobilized and pulled up into the chest, then anastomosed to the proximal 
stump of the esophagus. Image drawn by Sarah Alyssa Uy. 
 
Conclusion 
Surgery remains a very important part of cancer care. The surgical 
oncologist is an integral member of a multidisciplinary cancer team. 
Surgical oncologists are called on to obtain tissue for the diagnosis of 
cancer and to extirpate cancer with the goal of curing the patient of the 
malignancy. Surgery may also be used in selected patients to remove 
metastatic tumors. Finally, operations can be an important tool to relieve 
suffering resulting from cancer, even if cure is not possible. 
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Thought Questions 
1. In 2001 two studies were published that showed that patients with 
metastatic kidney cancer lived longer if they underwent removal of 
the cancerous kidney (radical nephrectomy) followed by treatment 
with alfa-interferon than if they simply received alfa-interferon without 
surgery. How does this kind of surgery, that intentionally leaves 
known metastatic disease in place, fit into the four general categories 
of oncologic surgery discussed in the chapter? Can you explain how 
removing a primary tumor while leaving distant metastatic disease 
behind could possibly result in an improvement in survival?2, 3 
References: NEJM. 2001;345(23):1655-9 and Lancet. 
2001;358(9286):966-70. 
Your answer: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expert Answer 
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2. A R0 resection of a tumor is the goal of any curative cancer surgery. 
Yet relapse after R0 resections can be very common, depending on 
the type and stage of cancer that is resected. Why should a cancer 
ever relapse if a surgeon is able to "get it all"? 
Your answer: 
 
 
 
 
 
 
 
 
 
 
 
 
Expert Answer 
Glossary 
Endoscopic- Performed by means of an endoscope 
Fistulas/ fistulae – An abnormal passage that leads from one organ to 
another organ or to the body surface 
Heal primarily- (primary intention)- Surgical closure of a wound to 
facilitate healing as opposed to secondary intention (wound is left open 
and healing occurs as the wound edges contract and granulation tissue 
forms) 
Laparoscopic- An abdominal operation done via a laparoscope– a 
usually rigid endoscope that is passed through a small incision in the 
abdominal wall into the peritoneal cavity 
Percutaneous- Performed through the skin 
Sentinel lymph node biopsy- Removal of a lymph node identified as the 
first node draining a tumor 
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History 
Cancer surgical advancement really opens with the first successful 
gastrectomy done in 1881 by Theodor Billroth at his internationally 
famous clinic in Vienna - to which much of the western world travelled for 
surgical instruction. 
A 40 year old woman, a patient who was dying from a gastric 
outlet obstruction, agreed to the experimental procedure and 
succumbed to liver and peritoneal metastases four months 
later. Billroth also performed the first laryngectomy and 
esophagectomy. 
Other examples of cancer surgery advances include: 
 Development of the modern radical resection of rectal cancer 
(abdominoperineal resection) by Ernest Miles at the Gordon 
Hospital for Diseases of the Rectum in London in 1908. 
 Development of the field of Neurosurgery by one of the great 
American surgical innovators, Harvey Cushing. Dr. Cushing 
developed the use of electrocautery in surgery with the help of an 
electrical engineer named William Bovie and as a medical student 
he established the practice of frequent vital sign checks during 
anesthesia. 
 The first single staged pancreaticotoduodenectomy for cancer was 
done by Allen O. Whipple in 1940 at Columbia. 
 The first pneumonectomy for lung cancer was done by Evarts 
Graham at the Barnes Hospital in St Louis in 1933. 
The radical mastectomy was devised and performed by William Stewart 
Halsted in 1882. This procedure is the hallmark of modern cancer 
surgery. Mastectomy for breast cancer was not a new operation and had 
been performed in a quick amputative fashion for centuries. The 
longstanding problem was that most breast tumors presented in 
advanced stage (T4 tumors) and recurred locally in the chest wall and 
glands under the arm. Microscopic tissue studies of the women who had 
died of their disease demonstrated cancer cells at some distance from 
the primary tumor, in lymph nodes, bones, liver, chest wall and lungs. 
Informed scientific opinion at the time, was that the seeds of cancer 
spread along fascial planes (to the muscles of the chest, ribs and 
vertebrae) and along the lymphatic channels to the nodes. Once those 
barriers were breached, the cancerous cells were able to travel in the 
bloodstream and establish colonies in liver, lung and brain. Based on this 
understanding of how cancer spread, Halsted’s operation was designed 
to control the disease by removing those dissemination conduits and 
contaminated tissue. Although he was not the first to arrive at these 
conclusions about what was needed for a successful operation, he 
employed a meticulous dissection technique for which he subsequently 
became well known and succeeded beyond what been accomplished to 
that point. His operation (the radical mastectomy) removed the breast 
and overlying skin widely, the pectoralis major and minor muscles and all 
the lymph node containing tissue from the apex of the axilla all the way 
to the latissmus dorsi muscle (which was also partly taken to encompass 
any spread down to the vertebrae where the tendon inserts). The bare 
chest wall was then skin grafted. The clinical results of his new operation 
were spectacular and paradigm changing: whereas practically everyone 
had recurred and died within two years, 80% of his patients were alive in 
that time frame. Halsted then made the observation that the extent of the 
primary tumor and the amount of nodal involvement by tumor cells 
determined the prognosis. This was the beginning of a cancer staging 
system. Halsted was a giant figure in the history of medicine and he 
made many fundamental contributions to the art and science of surgery 
in many areas which are still relevant today. The Halsted operation and 
its subsequent variations became the gold standard for breast cancer 
treatment until the 1980s when it was supplanted by operative 
approaches based on a different understanding of how cancer spreads 
and were designed for much smaller tumors. Despite the vast expansion 
of biomedical knowledge about cancer and control of cellular behavior in 
the century since Halsted described and reported his radical 
mastectomy; margins and lymph nodes remain an abiding focus for 
Surgical Oncologists today. 
Surgical oncology was originally the unintentional creation of a 
pathologist named James Ewing. Dr. Ewing was the founder and director 
of the Memorial Hospital in New York and believed that advances would 
come from surgeons (all general surgeons at that time) concentrating on 
the care of patients with cancer (there was no chemotherapy or medical 
oncologists at that point) and that these surgeons should become 
experts in the use of a new tool with anticancer properties. This tool was 
radium, which had also recently been discovered by Madam Curie in 
1898. Dr. Ewing was a tireless advocate for better care of cancer 
patients and overcoming the social stigma associated with the diagnosis. 
At that time, the diagnosis of “cancer” was not mentioned for the similar 
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type of fear it engendered. Time magazine honored Dr. Ewing for his 
work with its cover in 1931 titled “Cancer Man Ewing.” He inspired 
enormous affection and admiration in the students and young surgeons 
he gathered under his wing. This group ultimately formed an alumni 
association at Memorial Hospital; the acme of cancer care in the world. 
In 1940, they named themselves the James Ewing Society and in 1975 
this society became the Society of Surgical Oncology (SSO) which is the 
governing body for the Surgical Oncology specialty. 
The presence of metastases was evidence of systemic disease and as a 
consequence it was determined that only a systemic therapy such as 
chemotherapy could be employed. In fact, cancer surgery of metastatic 
disease was for many years considered vaguely disreputable; something 
only done by surgeons who were either ignorant or charlatans. That 
belief began to change in the 1960s when lung metastases from 
extremity osteosarcomas in young patients were being resected as part 
of aggressive treatment protocols (which included chemotherapy) 
developed at Memorial Sloan Kettering Cancer Center. It became 
apparent that some of these patients were cured. Around the same time 
in the 1970s, other cancer surgeons such as Martin Adson at the Mayo 
Clinic, James Foster at the University of Connecticut and Joseph Fortner 
at Memorial Sloan Kettering began resecting isolated solitary colorectal 
liver metastases and achieved some cures. This was unheard of, and the 
field began to change. Today, these kinds of operations are done 
frequently and for an expanding set of histologic types of cancer and 
indications. 
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